{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.185","value":"58.88"},{"groupId":"OG001","spread":"1.155","value":"60.33"}]}],"title":"At baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.187","value":"59.02"},{"groupId":"OG001","spread":"1.176","value":"61.83"}]}],"title":"At week 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.276","value":"60.77"},{"groupId":"OG001","spread":"1.249","value":"63.29"}]}],"title":"At week 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.368","value":"61.83"},{"groupId":"OG001","spread":"1.364","value":"64.06"}]}],"title":"At week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.590","value":"59.68"},{"groupId":"OG001","spread":"1.612","value":"65.07"}]}],"title":"At week 32"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.835","value":"63.43"},{"groupId":"OG001","spread":"1.991","value":"64.02"}]}],"title":"At week 40"}],"denoms":[{"counts":[{"groupId":"OG000","value":"566"},{"groupId":"OG001","value":"559"}],"units":"Participants"}],"description":"Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.","dispersionType":"Standard Error","groups":[{"description":"Cetuximab intravenous infusion of 400mg/m\\^2 for the first infusion then weekly intravenous infusion of 250mg/m\\^2. Bi-weekly Irinotecan infusion of 180mg/m\\^2, Folinic Acid infusion of 400mg/m\\^2 (racemic) or 200mg/m\\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\\^2 followed by a 46-hour continuous infusion of 2400mg/m\\^2 Number of Cycles: until progression or unacceptable toxicity develops","id":"OG000","title":"Cetuximab Plus FOLFIRI"},{"description":"Bi-weekly Irinotecan infusion of 180mg/m\\^2, Folinic Acid infusion of 400mg/m\\^2 (racemic) or 200mg/m\\^2 (L-form), 5-Fluorouracil bolus of 400mg/m\\^2 followed by a 46-hour continuous infusion of 2400mg/m\\^2 Number of Cycles: until progression or unacceptable toxicity develops","id":"OG001","title":"FOLFIRI Alone"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"1125 subjects (566 Cetuximab + FOLFIRI; 559 FOLFIRI alone) completed at least 1 evaluable questionnaire \\& were included in the Evaluable for QLQ-C30 population. Numbers at each timepoint were (Cetuximab + FOLFORI/FOLFORI alone, respectively): baseline 430/423; Week 8 421/390; Week 16 312/309; Week 24 255/244; Week 32 164/154; Week 40 122/96","reportingStatus":"POSTED","timeFrame":"at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006","title":"Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status","type":"SECONDARY","unitOfMeasure":"scores on a scale"}